Translational Cell and Gene Therapy mini-webinar series 

Translational Cell and Gene Therapy mini-webinar series 

Turbocharge your cell therapy research towards the clinics with our translational expertise

The Translational Cell and Gene Therapy mini-webinar series is a concise cluster of short webinars that grants an overview of Miltenyi Biotec’s portfolio of products and applications addressing important topics in the field of cell and gene therapy. Quickly tune in and get the latest information on the respective topics and learn about novel, cutting-edge technologies. 

As a catalyst of cell and gene therapy innovation, Miltenyi Biotec brings expertise and solutions to translational research driving insights from the lab bench to clinical applications in oncology and immunotherapies. The short presentations briefly delve into each topic and serve as a springboard for discussion. Your local sales contact can clarify any further questions directly and help guide your exploration of ideas and solutions locally.

Session 1 – Recordings coming soon

Research, manufacturing and analytics of engineered immune cells with a special focus on CAR T cells

Miltenyi Biotec’s CAR T cell ecosystem – from basic research to clinical manufacturing

Working with CAR T cells? Watch to this webinar and explore Miltenyi Biotec’s solutions to advance CAR T cell therapies – from basic research to process development and clinical manufacturing. Discover the products, tools and services that build on Miltenyi Biotec expertise to move your CAR T projects forward.
Bookmark the Translational Cell and Gene Therapy mini-webinar series and listen to the episode “Miltenyi Biotec’s CAR T cell ecosystem – from basic research to clinical manufacturing.” 

Speaker: Saskia Rösch, PhD

Saskia Rösch received her doctoral degree in biology from the University of Heidelberg/DKFZ, Germany, in 2017. She continued her studies in cancer immunotherapy as a postdoctoral fellow at the University Hospital in Heidelberg before joining Miltenyi Biotec as Global Product Manager for T Cell Immunology. 

Speaker: Melanie Rietenbach, PhD

Melanie Rietenbach is Global Product Manager for Miltenyi Biotec’s clinical engineered cells portfolio, including CAR T and CAR NK cells. For the past two years, she has been working with R&D and Clinical Development teams to develop and optimize tools that enable CAR T and CAR NK cell immunotherapy. Before that, Melanie was an Application Development and Clinical Product Specialist for over three years, managing technical support and application training.

New solutions for your engineered immune cell analytics

Melanie and Annika provide an update on technologies and resources available to upgrade your analytical toolbox for engineered immune cell analytics. They begin discussions with an overview of target discovery powered by the MACSima™ imaging platform to assess the immune context of disease. Next, they describe the advantages of StainExpress™ reagents and the Express Modes of the MACSQuantify™ Software for in-process (IPC) and quality control (QC) of engineered immune cells. 
Finally, they highlight the CAR Detection Reagents and other commercially available products to facilitate monitoring your cell product. Together, these constitute a dedicated set of tools to standardize and streamline your analytical assays and accelerate your development journey. 
Join us to learn the details in the Translational Cell and Gene Therapy mini-webinar series. Watch the episode “New solutions for your engineered immune cell analytics.” 

Speaker: Melanie Rietenbach, PhD

Melanie Rietenbach is Global Product Manager for Miltenyi Biotec’s clinical engineered cells portfolio, including CAR T and CAR NK cells. For the past two years, she has been working with R&D and Clinical Development teams to develop and optimize tools that enable CAR T and CAR NK cell immunotherapy. Before that, Melanie was an Application Development and Clinical Product Specialist for over three years, managing technical support and application training.

Speaker: Dr. Annika Graband

Annika is Miltenyi Biotec’s Product Manager responsible for the cell and gene therapy reagents portfolio, including CAR detection reagents and StainExpress™ dry antibody cocktails. During the past year, she has been working together with R&D to advance the development of tools that enable highly reliable and standardized cell and gene therapy analytics.

Session 2 – Recordings coming soon

Of PSCs and NK cells – a closer look at methods and analysis

Pluripotent stem cell culture and expansion: from research to clinical applications

In this webinar, Viola will first introduce our workflow for pluripotent stem cell (PSC) culture and maintenance. She will discuss our cell culture media products for PSC as well as well as our flow cytometry solution for quality control. Afterwards, Chao will outline the established workflow for GMP-compliant PSC expansion using the CliniMACS Prodigy® platform and the iPS-Brew GMP Medium, which could provide a ready-to-use solution for human PSC banking. 
Join us in the Translational Cell and Gene Therapy mini-webinar series. Listen to the episode “Pluripotent stem cell culture and expansion: from research to clinical applications” to find out more about our PSC portfolio. 

Speaker: Dr. Viola Stella Palladino

Viola Stella Palladino obtained her bachelor’s degree in biology and master´s degree in neurobiology at Sapienza University of Rome, Italy. After moving to Germany, she completed her PhD at Goethe University Frankfurt. Having joined Miltenyi Biotec as Global Product Manager in 2019, she is now Group Leader for Regenerative Medicine Research focusing on pluripotent stem cell, cardiovascular and neuroscience research.

Speaker: Dr. Chao Sheng

Chao conducted his PhD research at the Chinese Academy of Sciences in Beijing, China. He then continued his postdoctoral work on cell fate (re)programming at the University of Bonn and the German Center for Neurodegenerative Diseases in Bonn, Germany. As Product Manager for Regenerative Medicine Manufacturing, Chao works with colleagues to develop automated, closed, and scalable adherent stem cell cultivation workflows on the CliniMACS Prodigy® platform.

From CAR NK cell research to clinical NK cell engineering

Julia and Martha will discuss approaches to tackle questions in CAR NK cell research and enable a smooth transition into clinical CAR NK cell manufacturing. They will describe the best isolation strategies to obtain primary human NK cells and the optimal conditions to genetically modify NK cells. Integral to these processes is also the analysis of the phenotype and functional capacity of CAR NK cells via flow cytometry. Don’t miss the details! 
Want to learn more about CAR NK cell engineering? Tune in to the Translational Cell and Gene Therapy mini-webinar series and listen to the episode “From CAR NK cell research to clinical NK cell engineering.” 

Speaker: Dr. Julia Hengst

Julia Hengst received her doctoral degree in immunology from the Medical School Hannover, Germany, in 2017. She continued her research into innate immune responses as a postdoctoral fellow at the Medical School Hannover and the Karolinska Institute in Stockholm, Sweden, before joining Miltenyi Biotec as a Global Product Manager. Julia is responsible for the innate lymphoid cell research and clinical portfolio with emphasis on natural killer (NK) cells.

Speaker: Dr. Martha Elia Luevano Salinas

Martha Luevano is responsible for the clinical engineered cells portfolio at Miltenyi Biotec, including CAR T and CAR NK cells. For the last 6 years, she has been working with R&D and Clinical Development teams to advance the creation of tools that enable CAR T and CAR NK cell immunotherapies.

Session 3 – Recordings coming soon 

Viewing regulatory and SARS-CoV-2–specific T cells as clinical options

T cells in COVID-19: Translating research findings into clinical options

Evidence is mounting that SARS-CoV-2–specific T cells play an important role in recovering from COVID-19. Researchers have reported the presence of a SARS-CoV-2–specific memory T cell population in the blood of convalescent donors, and these cells have already been used to treat COVID-19 patients in a phase I clinical trial.
Miltenyi Biotec offers a complete workflow for the study of virus-specific T cells and the production of clinical-grade products for cell therapy applications.  Join the Translational Cell and Gene Therapy mini-webinar series and listen to the episode “T cells in COVID-19: Translating research findings into clinical options” to learn more about the evolving role of cell therapy in the field of infectious disease. 

Speaker: Kirsten Langeveld

Kirsten Langeveld has been with Miltenyi Biotec since 1997. Her main focus has been the establishment of technologies for ex vivo manipulation of grafts in hematopoietic stem cell transplantation. As Global Product Manager, she supports products that are used in cell therapy concepts to combat infections following stem cell transplantation. Kirsten graduated in chemical engineering in 1995.

Advance your clinical-grade Treg cell manufacturing with Miltenyi Biotec

The ability to suppress immune responses has made regulatory T (Treg) cells a promising target for immunotherapy. Tregs have shown their potential in a number of clinical applications, including the treatment of graft-versus-host disease (GvHD) after haploid stem cell transplantation (HSCT), post-transplant immunosuppression therapy after solid organ transplantation, and management of autoimmune diseases like Type 1 diabetes. 
Significant challenges for these treatments  begin with the effective isolation and enrichment of Treg cells from donor material. A subsequent hurdle is their efficient expansion to obtain clinically relevant cell numbers in a GMP-compliant manner.
Tune in to the Translational Cell and Gene Therapy mini-webinar series and learn how to advance your Treg cell manufacturing with Miltenyi Biotec’s comprehensive solutions for automated, clinical-grade Treg isolation and expansion. 

Speaker: Dr. Alina Steinbach

After completing a PhD and postdoctoral training in cancer immunotherapy at the German Cancer Research Center in Heidelberg, Germany, Alina joined Miltenyi Biotec as a Global Technical Support Specialist for research products and applications. Building on her expertise, she transitioned into Global Product Management in 2020 and is responsible for flow sorting applications.